WU
54
2
CA
40
4
NWSA
76
5
EXC
47
3
CTAS
64
-4
XRX
59
2
KMX
64
6
EQIX
57
3
NKE
42
3
AKAM
45
5
AN
61
3
NWS
83
8
C
48
-2
AAP
32
2
CAT
73
3
ROP
65
-3
MCO
77
-3
HSIC
56
12
CSCO
60
2
MCK
73
-2
WU
54
2
CA
40
4
NWSA
76
5
EXC
47
3
CTAS
64
-4
XRX
59
2
KMX
64
6
EQIX
57
3
NKE
42
3
AKAM
45
5
AN
61
3
NWS
83
8
C
48
-2
AAP
32
2
CAT
73
3
ROP
65
-3
MCO
77
-3
HSIC
56
12
CSCO
60
2
MCK
73
-2
Financhill
Back

InMed Pharmaceuticals 10K Form

Sell
36

INM
InMed Pharmaceuticals

Last Price:
0.26
Seasonality Move:
-22.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive INM News And Ratings

See the #1 stock for the next 7 days that we like better than INM

INM Financial Statistics

Sales & Book Value

Annual Sales: $4.14M
Cash Flow: $-1.86M
Price / Cash Flow: 0
Annual Sales: $2.25
Price / Book: 0.13

Profitability

EPS (TTM): -1.27000
Net Income (TTM): $-6.35M
Gross Margin: $1.4M
Return on Equity: -51.92%
Return on Assets: -44.15%

InMed Pharmaceuticals Earnings Forecast

Key InMed Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 23 years for INM is 33.93%.
  • The Selling, General & Administrative Expenses for INM have been equal to 141.40% of Gross Profit Margin.
  • The Research & Development expenses have been 90.24% of Revenue.
  • The Interest Expense is -3.53% of Operating Income.
  • Per Share Earnings over the last 23 years have been positive in 14 years.

InMed Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: INM
Website: inmedpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.03
Quick Ratio: 5.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

INM Technical Analysis vs Fundamental Analysis

Sell
36
InMed Pharmaceuticals (INM) is a Sell

Is InMed Pharmaceuticals a Buy or a Sell?